ADMA Biologics, Inc.
ADMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $134 | $122 | $115 | $118 |
| % Growth | 10% | 6.3% | -2.3% | – |
| Cost of Goods Sold | $59 | $55 | $54 | $54 |
| Gross Profit | $76 | $67 | $61 | $63 |
| % Margin | 56.3% | 55.1% | 53.2% | 53.9% |
| R&D Expenses | $2 | $1 | $1 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $23 | $22 | $24 | $23 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $1 | $1 |
| Operating Expenses | $25 | $24 | $26 | $25 |
| Operating Income | $51 | $43 | $35 | $38 |
| % Margin | 38% | 35.1% | 30.4% | 32.6% |
| Other Income/Exp. Net | -$3 | -$3 | -$1 | -$4 |
| Pre-Tax Income | $48 | $40 | $33 | $35 |
| Tax Expense | $11 | $6 | $7 | -$77 |
| Net Income | $36 | $34 | $27 | $112 |
| % Margin | 27.1% | 28.1% | 23.4% | 95.2% |
| EPS | 0.15 | 0.14 | 0.11 | 0.47 |
| % Growth | 7.1% | 27.3% | -76.6% | – |
| EPS Diluted | 0.15 | 0.14 | 0.11 | 0.46 |
| Weighted Avg Shares Out | 239 | 241 | 238 | 236 |
| Weighted Avg Shares Out Dil | 245 | 249 | 245 | 246 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $1 |
| Interest Expense | $2 | $2 | $2 | $3 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | $51 | $44 | $37 | $40 |
| % Margin | 38.2% | 36.1% | 32.6% | 33.6% |